RxDoctor Payments Data

Shantaniece Sherrell, NP

Nurse Practitioner · Avon, INNPI 1609203884

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $16,760 of the $24,176 with a category attached, or 69.3%. 60 manufacturers reported payments, led by Lilly USA, LLC at 27.6% of the total. Reporting peaked in 2024 at $9,053 and has fallen 55.3% since, to $4,045 in 2025. Among nurse practitioner clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$24,176in general payments, 2019–2025

Across 856 payments — averaging $28.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$7K
  • Novartis$2K
  • Johnson & Johnson$1K
  • Merck$1K
  • Daiichi Sankyo Inc.$925
  • E.r. Squibb & Sons, L.L.C.$860
  • plus $11K from 54 others

What the payments were for

  • Consulting fees$6,30026%
  • Food & beverage$16,76069%
  • Education$7173%
  • Other$3992%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC22$6,662
Novartis114$1,976
Johnson & Johnson(2 entities)38$1,199
Merck44$1,035
Daiichi Sankyo Inc.59$925
E.r. Squibb & Sons, L.L.C.45$860
AstraZeneca(2 entities)37$800
Sanofi30$798
Pfizer39$760
Amgen32$728
Bristol Myers Squibb38$656
Eisai Inc.34$650
Incyte Corporation29$561
Gilead(2 entities)21$456
Exelixis Inc.12$415
Takeda Pharmaceuticals U.S.A., Inc.14$378
Seagen Inc.16$336
Pharmacyclics LLC, An Abbvie Company16$318
AbbVie13$309
Astellas Pharma US Inc14$282
Genentech USA, Inc.16$262
Boehringer Ingelheim11$221
Acrotech Biopharma Inc.9$193
Beigene USA, Inc.8$191
Sanofi-aventis U.S. LLC2$176
Ipsen Biopharmaceuticals, Inc8$174
Bayer6$169
EMD Serono, Inc.7$151
Jazz Pharmaceuticals Inc.6$143
Regeneron Healthcare Solutions, Inc.6$138
Puma Biotechnology, Inc.8$133
Servier Pharmaceuticals LLC6$129
Pharmaessentia USA Corporation6$125
Global Blood Therapeutics, Inc.3$123
Array Biopharma Inc7$107
Genmab U.S., Inc.5$101
GSK6$97
Tersera Therapeutics LLC4$95
Coherus Oncology, Inc.4$93
Rigel Pharmaceuticals, Inc.3$89
Morphosys, US Inc.5$86
Blueprint Medicines Corporation4$79
Sobi, Inc5$78
Karyopharm Therapeutics Inc.3$72
Adaptive Biotechnologies Corporation3$67
Mirati Therapeutics, Inc.2$66
Pharmacosmos Therapeutics Inc.3$60
Geron Corporation2$52
Beone Medicines USA, Inc.2$50
Syndax Pharmaceuticals, Inc.2$49
Agios Pharmaceuticals, Inc.2$42
Immunocore Limited2$39
Octapharma USA, Inc.1$36
Acceleron Pharma, Inc.2$34
Corcept Therapeutics1$29
Taiho Oncology, Inc.2$28
Springworks Therapeutics, Inc.1$24
Novocure Inc.1$24
Stemline Therapeutics Inc.1$22
Sun Pharmaceutical Industries Inc.1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,176 in reported general payments places this provider in the 95th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$56,837
Medicare patients
304
Services billed
765

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban50$32,989
EliquisApixaban33$29,917
Exemestane19$6,421
Anastrozole94$1,521
Letrozole43$1,181
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen35$747
Oxycodone Hcl50$573
Gabapentin35$416
Tamoxifen Citrate17$321
Morphine Sulfate ErMorphine Sulfate11$285
Hydroxyurea27$228
Acyclovir18$169
Famotidine14$152
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen11$72
Prednisone13$27

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$1,199$32,98950 claims
PfizerEliquis$760$29,91733 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in Avon

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →